Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Nurix Therapeutics Swings To Profit In Q3 On Roche Licensing Revenue

(RTTNews) - Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period, primarily reflecting a major licensing revenue from its collaboration with Swiss drug major Roche Holding AG

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Read the original at nasdaq.com →

More in Finance & Markets

More from Tuesday 13 October →